Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Astra_Zeneca's_monoclonal_antibodies
|
| gptkbp:activities |
neutralizes SARS-Co V-2
|
| gptkbp:appointed_by |
intramuscular injection
|
| gptkbp:approves |
children under 12
December 2021 COVID-19 prevention |
| gptkbp:associated_with |
reduced hospitalization rates
reduced transmission risk reduced severe disease rates |
| gptkbp:can_be_used_with |
other COVID-19 therapies
|
| gptkbp:clinical_trial |
Phase 3
pre-exposure prophylaxis prophylactic treatment NC T04625725 NC T04797821 |
| gptkbp:contains |
gptkb:cilgavimab
gptkb:tixagevimab |
| gptkbp:contraindication |
history of severe allergic reactions
|
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:dosage_form |
300 mg
|
| gptkbp:emergency_services |
gptkb:FDA
|
| gptkbp:encouraged |
before administration
|
| gptkbp:frequency |
every 6 months
|
| https://www.w3.org/2000/01/rdf-schema#label |
Evusheld
|
| gptkbp:influenced_by |
emerging variants of concern
|
| gptkbp:invention |
gptkb:temple
|
| gptkbp:is_available_in |
vials
|
| gptkbp:is_compared_to |
placebo
|
| gptkbp:is_considered |
post-exposure prophylaxis
|
| gptkbp:is_effective_against |
Omicron variant
over 80% in preventing symptomatic COVID-19 |
| gptkbp:is_studied_in |
long-term immunity
immunocompromised populations |
| gptkbp:is_subject_to |
regulatory review
|
| gptkbp:is_used_for |
vaccination
|
| gptkbp:marketed_as |
gptkb:brand
|
| gptkbp:part_of |
COVID-19 vaccination strategy
COVID-19 treatment guidelines public health response to COVID-19 |
| gptkbp:provides_information_on |
updated regularly
|
| gptkbp:release_region |
multiple countries globally
|
| gptkbp:requires |
medical supervision
cold chain logistics |
| gptkbp:research |
gptkb:The_New_England_Journal_of_Medicine
|
| gptkbp:side_effect |
fatigue
headache nausea allergic reactions injection site reactions |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:suitable_for |
gptkb:CDC
gptkb:WHO active COVID-19 infection |
| gptkbp:target_audience |
adults and adolescents
|
| gptkbp:used_in |
clinical settings
immunocompromised patients |